Reference : The antiangiogenic factor, 16-kDa human prolactin, induces endothelial cell cycle arr...
Scientific journals : Article
Human health sciences : Endocrinology, metabolism & nutrition
http://hdl.handle.net/2268/12223
The antiangiogenic factor, 16-kDa human prolactin, induces endothelial cell cycle arrest by acting at both the G(0)-G(1) and the G(2)-M phases
English
Tabruyn, Sébastien mailto [Université de Liège - ULg > Département des sciences de la vie > GIGA-R : Biologie et génétique moléculaire >]
Nguyen, Ngoc-Quynh-Nhu mailto [Université de Liège - ULg > Département des sciences de la vie > Biologie et génétique moléculaire >]
Cornet, Anne [Université de Liège - ULg > Département de morphologie et pathologie > Pathologie spéciale et autopsies >]
Martial, Joseph mailto [Université de Liège - ULg > Département des sciences de la vie > GIGA-R : Biologie et génétique moléculaire >]
Struman, Ingrid mailto [Université de Liège - ULg > Département des sciences de la vie > Biologie et génétique moléculaire >]
Jul-2005
Molecular Endocrinology
Endocrine Soc
19
7
1932-1942
Yes (verified by ORBi)
International
0888-8809
Chevy Chase
[en] The 16-kDa N-terminal fragment of human prolactin (16K hPRL) is a potent antiangiogenic factor that has been shown to prevent tumor growth in a xenograph mouse model. In this paper we first demonstrate that 16K hPRL inhibits serum-induced DNA synthesis in adult bovine aortic endothelial cells. This inhibition is associated with cell cycle arrest at both the G(0)-G(1) and the G(2)-M phase. Western blot analysis revealed that 16K hPRL strongly decreases levels of cyclin D1 and cyclin B1, but not cyclin E. The effect on cyclin D1 is at least partially transcriptional, because treatment with 16K hPRL both reduces the cyclin D1 mRNA level and down-regulates cyclin D1 promoter activity. This regulation may be due to inhibition of the MAPK pathway, but it is independent of the glycogen synthase kinase-3 beta pathway. Lastly, 16K hPRL induces the expression of negative cell cycle regulators, the cyclin-dependent kinase inhibitors p21(cip1) and p27(kip1). In summary, 16K hPRL inhibits serum-induced proliferation of endothelial cells through combined effects on positive and negative regulators of cell cycle progression.
Giga-Cancer
http://hdl.handle.net/2268/12223
10.1210/me.2004-0515

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
tabruyn 2005.pdfPublisher postprint354.62 kBRequest copy
Open access
Tabruyn2005_pp.pdfAuthor postprint2.87 MBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.